ClinicalTrials.gg
RecruitingNCT06123000Updated Apr 10, 2025

Modified Widman Flap vs Fibre Retention Osseous Resective Surgery

An interventional study of Modified Widman Flap (MWF) and Fiber Retention Osseous Resective Surgery (FibReORS) in Periodontitis, Periodontal Pocket and Periodontal Attachment Loss, sponsored by University of Florence. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.

Primary conditionPeriodontal PocketRegistry: PeriodontitisReclassifiedWhy we changed it
Registry
Periodontitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Periodontal Pocket
Why
  1. The study's listed conditions name Periodontal Pocket, a narrower term within Periodontitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Florence · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Periodontal Pocket with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Periodontal Pocket · Italy.

Planned enrollment
9th of 17
36 · median 36
Started
2024
with 3 others
No phase
15 of 20
5 open now
Registered
14th of 20
by date
Lead sponsor
3 of 20
University of Florence

Among the 20 studies in Periodontal Pocket with a site in Italy, this one is the 9th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2024, is one of 15 with no phase, and was the 14th registered.

Periodontal Pocket

130 studies on the registry are indexed under Periodontal Pocket; 35 are open to participants now.

Browse Periodontal Pocket studies →

Open to participants now

5 of the 20 studies in Periodontal Pocket with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 23 Periodontal Pocket studies recruiting now, 14 (61%) set no upper age limit and 4 (17%) stop at 75 or younger; 3 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Periodontal Pocket with a site in Italy, or all of them as a file.
02

Study summary

The treatment of periodontitis should be carried out in an incremental manner, first by achieving adequate patient's oral hygiene practices and risk factor control during the first step of therapy and then, during the second step of therapy, by professional elimination (reduction) of supra and subgingival biofilm and calculus.

If the endpoints of therapy (no periodontal pockets >4 mm with bleeding on probing, BoP, or deep pockets ≥5 mm) have not been achieved, the third step of therapy should be implemented.

In fact, residual pockets following step 1 and 2 of periodontal treatment are associated with increased risk of periodontal disease progression in the long-term as reported by Claffey \& Egelberg in1995. Residual probing depth (PPD) ≥5 mm after active therapy is a risk factor for disease progression and tooth loss during supportive periodontal therapy (SPT), suggesting that additional treatment of residual pockets is strongly recommended.

The third step of treatment includes the following interventions: repeated subgingival instrumentation, access flap periodontal surgery, resective periodontal surgery, regenerative periodontal surgery.

In case of residual pockets associated with shallow-moderate infrabony defects at posterior teeth, where both regenerative therapy and non-surgical re-instrumentation are usually not indicated, access flap procedures (i.e., the Modified Widman Flap, MWF) and the Osseous Resective Surgery (ORS) are considered two of the most viable options.

The value of these surgical techniques has been tested over the years by different clinical trials, and the choice of a surgical approach still relies mainly on the decision-making process of the surgeon, since the long-term outcomes of the different periodontal surgical procedures are similar, as highlighted by a recent systematic review.

Nevertheless, one the main criticism that have been moved against ORS, lies on the fact that the side effects (i.e., gingival recessions) seem to be more severe for ORS surgery, when compared with MWF.

In the early 2000s, Carnevale proposed the Fibre Retention Osseous Resective Surgery (FibReORS), an approach that leads to a more conservative bone resection to eliminate infrabony defects and establish a positive bony architecture than the conventional ORS. Indeed, this one, based on the histological findings by Gargiulo et al. (1961), uses the level of the connective tissue attachment - rather than the bottom of the osseous defect - as the reference to apply the principles of ORS.

Two randomized clinical trials demonstrated that FibReORS is similarly effective as ORS for PPD reduction with less final gingival recessions (REC), clinical attachment loss (CAL) patient morbidity.

Nevertheless, no studies have ever directly compared FibreORS with MWF. Therefore, the aim of this randomized clinical trial (RCT) is to compare the efficacy of FibReORS versus MWF in the treatment of periodontal pockets associated with infrabony defects ≤3 mm at posterior natural teeth.

Objectives

The experimental hypothesis is:

FibReORS is superior to MWF in achieving PPD closure (PPD \<4 mm without BoP) at posterior teeth associated with shallow-moderate infrabony defects.

03

Conditions studied

  • Periodontitis
  • Periodontal Pocket
  • Periodontal Attachment Loss

Browse trials for

04

In context

Periodontal Pocket Reclassified

130 studies on the registry are indexed under Periodontal Pocket; 35 are open to participants now.

This study's planned enrollment of 36 is above the median of 30 across 113 interventional studies indexed under Periodontal Pocket.

Browse Periodontal Pocket studies →

Lead sponsor

University of Florence is the lead sponsor of 76 studies on the registry; 17 are open to participants now.

Compared within Periodontal Pocket, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Periodontitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • Patients affected by periodontitis;
  • No systemic disease or pregnancy;
  • No systemic antibiotic therapy in 6 months preceding the enrollment;
  • Smoking ≤ 20 cigarettes/day;
  • Full-mouth plaque score (FMPS) and full- mouth bleeding score (FMBS) ≤ 15%;
  • Residual periodontal pocket ≥5 mm with bleeding on probing at posterior natural teeth;
  • Experimental pocket associated with a detectable infrabony defect ≤ 3mm at x-ray;
  • No history of periodontal surgery at the experimental site.

Exclusion criteria

Exclusion Criteria:

  • Undetectable cemento-enamel junction (CEJ) at experimental teeth;
  • Severe furcation involvement (class II and III);
  • Abutment for prosthetic rehabilitation;
  • Periodontal Pockets associated with infrabony defect >3 mm;
  • Horizontal bone loss higher than 1/3 of the root length at experimental teeth;
  • Severe tooth mobility at baseline (class 2 or 3).
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    Modified Widman Flap (MWF)

    At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.

    Procedure: Modified Widman Flap (MWF)

  • Experimental
    Fiber Retention Osseous Resective Surgery (FibReORS)

    At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed

    Procedure: Fiber Retention Osseous Resective Surgery (FibReORS)

Interventions

  • ProcedureModified Widman Flap (MWF)

    At buccal and lingual/palatal side, a full thickness incision parallel to the long axis of the tooth will be performed. In case of buccal or lingual pockets deeper than 2 mm, this initial incision will be placed approximately 1 mm apically to the free gingival margin. All soft tissues will be removed from the bony surface of intrabony defects. In case of incomplete adaptation between the flaps and the teeth or between the buccal and lingual flaps, the flaps will be thinned, and an amount of bone removal will be performed. Only osteoplasty will be allowed, while these patients will not receive ostectomy.

  • ProcedureFiber Retention Osseous Resective Surgery (FibReORS)

    At the buccal sites, internally beveled incisions will be positioned at intra-sulcular or extra-sulcular level based on the apico-coronal dimension of the keratinized tissue. A split thickness flap beyond the MGJ will be then elevated. Vertical releasing incisions will be used to augment surgical access as needed. At lingual site split-full-thickness flap was used positioning an extra-sulcular internally beveled primary incision, while at the palatal area, the thinned palatal flap technique will be performed.

07

What researchers measure

Primary outcomes

  1. Periodontal Pocket Closure

    Distance between the tip of a periodontal probe and the gingival margin \< 4 mm, without bleeding.

    Time frame: Six months after the procedure

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2025, 12 months after the start.

Of 59 non-industry interventional studies with no phase under Periodontal Pocket, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 26. This study's planned 12 months is below that.

Counting every sponsor, half of 63 studies reached it within 16 months; a quarter within 9 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2023
First posted
Nov 8, 2023
StartActual
Oct 21, 2024
Primary completionEst.
Oct 21, 2025
CompletionEst.
Oct 21, 2026
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06123000
Lead sponsor
University of Florence
Responsible party
Luigi Barbato (Principal Investigator, University of Florence) — Principal investigator
First posted
Nov 8, 2023
Start date
Oct 21, 2024
Primary completion
Oct 21, 2025 (estimated)
Completion
Oct 21, 2026 (estimated)
Last update
Apr 10, 2025

Study contacts

Luigi Barbato, Dr.
Contact
luigi.barbato@unifi.it
3299457556 ext. +39

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion